Lead Product(s) : Plonmarlimab
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study aimed to determine the safety, efficacy and effects on cytokine levels following a single dose of 6 mg/kg of plonmarlimab or placebo in patients with severe COVID-19.
Product Name : TJM2
Product Type : Antibody
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Plonmarlimab
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable